24/7 Customer Support
The Global Non-Opioid Pain Relief Device Market, which was valued at US$ 5,031 million in 2022, is expected to reach US$ 10,311 million by 2031, signaling a significant growth trajectory at a CAGR 8.3% during the forecast period 2031-2031.
This expansion is primarily fueled by the rising demand for non-invasive, non-pharmacological pain management solutions amidst the escalating opioid crisis, and an aging global population experiencing chronic pain. In 2022, North America was the dominant region due to its advanced healthcare system and high consumer awareness. Asia Pacific is expected to emerge as a fast-growing market, courtesy of its vast population, rising healthcare expenditure, and increasing adoption of advanced medical devices.
The sector's future landscape seems promising, with innovations focused on smart, connected devices offering personalized pain management. This advancement is in line with the overall healthcare trend towards personalized medicine. Additionally, regulatory support for non-opioid solutions and increased investment in pain management research are expected to further propel the market growth.
Aiding the sector's future growth is the anticipated rise of AI and IoT in pain management, promising personalized and efficient care. However, challenges persist. For instance, the high cost of advanced devices may restrict market expansion in low-income countries, where nearly 80% of chronic pain sufferers reside.
However, high device costs and limited accessibility in emerging non-opioid pain relief device markets may pose challenges. Strategies for cost-effective production, insurance coverage improvements, and localized marketing approaches are essential to address these hurdles.
To Get more Insights, Request A Free Sample
Chronic pain, which affects over 1.5 billion people worldwide, is an escalating global health concern. This equates to a prevalence rate of over 20% in the adult population, and the number is even more staggering among older adults, with around 50% reporting suffering from chronic pain. Conditions such as arthritis, neuropathy, and lower back pain are particularly prevalent in this demographic.
Moreover, the world's population is rapidly aging. The United Nations estimates that the global population of people aged 60 and over will double from 900 million in 2015 to approximately 2 billion by 2050. As our global society ages, the demand for pain relief that doesn't rely on opioids is expected to escalate. This increase in chronic pain, coupled with an aging population, creates a potent driver for the Non-Opioid Pain Relief Device market.
The opioid crisis, particularly in the US, has put a spotlight on the urgent need for non-opioid alternatives for pain management. In 2019, an alarming 70.6% of drug overdose deaths in the US involved an opioid. The awareness and understanding of the adverse effects of opioid medications, including dependency, addiction, and the risk of overdose, are growing among both healthcare professionals and the general public.
In response to this crisis, medical device manufacturers are channeling their resources and research into developing effective non-opioid alternatives. As the understanding of the opioid crisis deepens and continues to pervade public consciousness, this driver for the Non-Opioid Pain Relief Device market is likely to remain significant.
Despite the considerable potential of the Non-Opioid Pain Relief Device market, the high cost of these devices poses a significant constraint, especially in emerging economies. Many of these innovative non-opioid pain relief devices, developed using cutting-edge technology, are priced out of reach for a significant portion of the global population. This challenge is exacerbated in low-income countries, home to nearly 80% of chronic pain sufferers worldwide, where healthcare infrastructure often lacks the capability for widespread device distribution.
Furthermore, awareness and knowledge about these devices are frequently limited in these regions, creating a barrier to adoption even when devices are available. High costs, coupled with issues of accessibility and awareness, could seriously limit the potential growth of this market unless innovative solutions and strategies are implemented to address these challenges.
The neuromuscular pain segment holds a commanding presence in the global non-opioid pain relief device market. In 2022 alone, this sector generated a substantial revenue of $1,911.9 million, constituting nearly 38% of the total market size of $5,031 million. This dominance can be attributed to an increasingly sedentary lifestyle and a rise in jobs that require prolonged sitting, leading to a surge in incidences of chronic back pain.
As per the World Health Organization, approximately 60% to 70% of adults in industrialized countries have experienced low back pain. The American Chiropractic Association further underscores this issue, estimating that back pain is the single leading cause of disability, preventing many people from engaging in work or other everyday activities.
However, a notable shift is anticipated in the future landscape of the non-opioid pain relief device market. The pain associated with diabetic neuropathy is projected to grow at a substantial rate of 10%. This forecast is built on the rising incidence rates of diabetes worldwide. The International Diabetes Federation estimates that 463 million adults (20-79 years) were living with diabetes in 2019, and this number is expected to rise to 700 million by 2045.
Moreover, an increase in the prediabetic population also bolsters this trend. According to the Centers for Disease Control and Prevention (CDC), in 2020, over 88 million American adults—approximately 1 in 3—had prediabetes. With these numbers, the growth in the segment addressing diabetic neuropathy pain is expected to make a substantial impact on the market in the near future. This highlights the need for targeted interventions and product offerings to cater to this burgeoning demand.
Implantable device technology, a subset of the electroanalgesia segment, encompasses products that require surgical implantation within the body for chronic pain management. As of 2022, the market for these implantable devices was valued at $767.2 million in the global non-opioid pain relief device market. Forecasts predict a promising upward trend, with a projected compound annual growth rate (CAGR) of 7.8% through 2031.
In the electroanalgesia device market, implantable devices held a dominant share of 77.6% in 2022. This predominance can be attributed to a few key factors. Firstly, these devices, which include spinal cord stimulators and peripheral nerve stimulators, have been proven to be highly effective in managing chronic pain conditions like failed back surgery syndrome, complex regional pain syndrome, and severe nerve-related pain or numbness.
To Understand More About this Research: Request A Free Sample
As of 2018, the global pain relief device market by end users was dominated by hospital. This segment attributed to 63.7% of the total non-opioid pain relief device market (by end users) in 2018 due to dominance of implantable electroanalgesia devices. In addition, pain management center as an end user is anticipated to be the fastest growing segment with a CAGR of 9.5% during the forecast period 2023-2031, owing to the awareness among the population regarding the centers providing specified treatment for the pain. Furthermore, the homecare segment comprises 14.3% of the end users. It was valued at $528.2 million in 2018 and is anticipated to grow to $1,336.5 million in 2029 with a CAGR of 8.8% during the forecast period 2018-2029.
According to a study published in the journal Neuromodulation, about 50-80% of patients experienced significant pain relief from spinal cord stimulation. Similarly, the British Journal of Anesthesia reports peripheral nerve stimulation to be effective in 60-80% of cases. Secondly, implantable devices can offer long-term relief without the systemic side effects often associated with opioid medications, making them a preferable choice for both clinicians and patients aiming for sustainable and safe pain management solutions.
Moreover, the rising prevalence of chronic pain worldwide, along with an increase in the aging population susceptible to chronic pain conditions, is expected to drive the demand for these devices further. Hence, it's anticipated that the implantable device market will continue to hold a significant position in the global Non-Opioid Pain Relief Device Market throughout the decade.
In 2022, North America held the largest share of the global non-opioid pain relief device market, contributing over $1,898.9 million, representing approximately 35% of the total market size of $5,448.57 million. The region's dominance in the market can be attributed to several factors.
The high prevalence of chronic pain disorders is a primary driver. According to the US Centers for Disease Control and Prevention (CDC), approximately 20% of US adults had chronic pain in 2019. This proportion corresponds to a significant consumer base for non-opioid pain relief devices. Moreover, North America has been significantly impacted by the opioid crisis, leading to heightened awareness of the risks associated with opioid use and a shift towards non-opioid alternatives. For example, in 2019, opioid overdoses accounted for nearly 70% of drug overdose deaths in the US.
North America's advanced healthcare infrastructure, higher healthcare expenditure, and quicker adoption of innovative medical devices further support its leading position in this non-opioid pain relief device market. The region is anticipated to maintain its dominance in the future, propelled by these continuing trends.
Europe, being the second-largest market, is also demonstrating strong growth dynamics. Predicted to grow at a CAGR of 8.6% during the forecast period, Europe's growth can be attributed to similar factors as North America, including an aging population, rising prevalence of chronic pain disorders, and increasing healthcare expenditure. According to Eurostat, around 20% of the EU population was 65 years or older in 2020, and this demographic trend indicates a growing demand for effective pain management solutions.
Moreover, European healthcare systems have been investing significantly in the adoption of innovative medical technologies, further fueling the growth of the non-opioid pain relief device market in the region. By these indicators, the future landscape of the non-opioid pain relief device market looks promising for both North America and Europe.
Market Segmentation Overview :
By End User
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.SPEAK TO AN ANALYST